Cuba's COVID-19 Vaccines Not On New List Of "Approved Vaccines" For Entry Into The United Kingdom
/Government Of The United Kingdom
London, England
10 January 2022
“Approved vaccines: You must have had a complete course of one of the following vaccines at least 14 days (the day you have your final dose does not count as one of the 14 days) before you arrive in England:
Covaxin
Moderna
Janssen (single dose vaccine)
Novavax (Nuvaxovid and Covovax)
Oxford/AstraZeneca
Pfizer BioNTech
Sinopharm Beijing
Sinovac-CoronaVac
Formulations of these vaccines, such as AstraZeneca Covishield, AstraZeneca Vaxzevria and Moderna Takeda, also qualify as approved vaccines.”
The Republic of Cuba is not included among the list of "Countries with an approved proof of vaccination and examples of proof required- List of countries and territories with approved proof of vaccination for travel to England and examples of proof of vaccination."
https://www.gov.uk/guidance/countries-with-approved-covid-19-vaccination-programmes-and-proof-of-vaccination?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=475a10ca-034e-4bd7-a660-6377108f7fdd&utm_content=immediately
Reuters
London, United Kingdom
20 December 2021
Excerpts:
Cuba has said its homegrown, protein-based Abdala, Soberana 02 and Soberana Plus shots give upwards of 90% protection against symptomatic COVID-19 when offered in three-dose schemes.
However, Cuba has not yet published results of its large-scale clinical trials in peer-reviewed journals, nor has it submitted the documents required by the World Health Organization for approval of its vaccines, according to the WHO's online tally. As a result, some public health experts in other countries remain leery of recommending them until the results are vetted. "They have been slow to publish results," said Moss. "If (the vaccines) got WHO qualification... that could be really important globally."
The documents and data necessary for vetting the Soberana vaccines, developed by Cuba's Finlay Vaccine Institute, will be delivered to the WHO in the first quarter of 2022, Vicente Verez, Finlay's head, told Reuters. Verez said WHO standards, which assess not only the vaccine but also manufacturing facilities, had slowed Cuba down. "It's a first-world standard," Verez said, noting the expense involved to bring facilities to that level. "We need to advance on our manufacturing process to ensure that when we apply, we get WHO pre-qualification." Verez said Cuba is negotiating with both Canada and Italy to produce its vaccines in those countries for export to regions in need, including Africa.
Prensa Latina News Agency
Havana, Republic Of Cuba
20 January 2022
By: Aleynes Palacios Hurtado
According to a tweet by the Finlay Vaccine Institute (IFV, in Spanish), which developed this vaccine, the publication addresses the advantages of using OMVs (Outer Membrane Vesicles) as adjuvants in protein subunit vaccines against this coronavirus, which causes the Covid-19 pandemic. This institute tweeted that “Cuban science keeps on building scientific evidence of the Soberana vaccines. This recent article is about Soberana 01’s development and immunogenicity.” Entitled “A Covid-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles,” the Chemical Biology article reports that it was observed that, with Soberana 01, the formulation with OMVs triggers a greater neutralizing effect against RBD mutants in alarming SARS-CoV-2 variants, including the RBD triple mutant of the Beta one. It also reported that the advantages of using OMVs as adjuvants in protein subunit vaccines against this virus were proven. The satisfactory results justify the continuation of the study with Phase 2 and Phase 3 clinical trials with this vaccine candidate. Cuba developed three Covid-19 vaccines (Soberana 02, Soberana Plus and Abdala) and two vaccine candidates: Soberana 01 and Mambisa, the latter to be administered nasally, developed by the Center for Genetic Engineering and Biotechnology (CIGB, in Spanish), which also developed Abdala, the first vaccine created in Latin America to fight Covid-19.
